ORCID as entered in ROS

Select Publications
2025, 'Author Correction: Bullous pemphigoid (Nature Reviews Disease Primers, (2025), 11, 1, (12), 10.1038/s41572-025-00595-5)', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00605-6
,2025, 'Bullous pemphigoid', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00595-5
,2025, 'The development and validation of an investigator global assessment score for keratosis pilaris', Journal of the European Academy of Dermatology and Venereology, 39, pp. e350 - e352, http://dx.doi.org/10.1111/jdv.20326
,2025, 'Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece', JID Innovations, 5, http://dx.doi.org/10.1016/j.xjidi.2024.100339
,2025, 'Assessment of a Real-Time PCR Assay for the Detection of Dermatophytosis by Sampling With an Adhesive Tape Technique', Australasian Journal of Dermatology, 66, pp. e60 - e61, http://dx.doi.org/10.1111/ajd.14415
,2025, 'Ethics of publication mills and payment for guaranteed authorships', Journal of the American Academy of Dermatology, 92, pp. 666 - 667, http://dx.doi.org/10.1016/j.jaad.2024.10.034
,2025, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, 39, pp. 340 - 349, http://dx.doi.org/10.1111/jdv.20149
,2025, 'Body image disturbance has severe psychosocial impacts in patients suffering from autoimmune blistering diseases', Journal of the European Academy of Dermatology and Venereology, 39, pp. 253 - 254, http://dx.doi.org/10.1111/jdv.20491
,2025, 'Bullous pemphigoid burden of disease, management and unmet therapeutic needs', Journal of the European Academy of Dermatology and Venereology, 39, pp. 290 - 300, http://dx.doi.org/10.1111/jdv.20313
,2025, 'Colchicine as a treatment option for inherited epidermolysis bullosa.', Clin Exp Dermatol, http://dx.doi.org/10.1093/ced/llaf016
,2025, 'Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires', Journal of Dermatology, http://dx.doi.org/10.1111/1346-8138.17707
,2025, 'Leveraging space innovations for cancer breakthroughs on Earth', Trends in Cancer, http://dx.doi.org/10.1016/j.trecan.2025.02.003
,2025, 'Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External Experts', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17668
,2025, 'Toward gender equity for all members of the academic dermatology community', Clinics in Dermatology, http://dx.doi.org/10.1016/j.clindermatol.2025.01.004
,2024, 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council', The British journal of dermatology, 192, pp. 135 - 143, http://dx.doi.org/10.1093/bjd/ljae342
,2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
,2024, 'Digital twins in dermatology, current status, and the road ahead', npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
,2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, 41, pp. 4418 - 4432, http://dx.doi.org/10.1007/s12325-024-02992-w
,2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, 42, pp. 723 - 726, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
,2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', eClinicalMedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
,2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308
,2024, 'Dermatology Journal Advisory Boards and editorial independence', JAAD International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
,2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
,2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023
,2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1504 - 1513, http://dx.doi.org/10.1111/jdv.20027
,2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 41, 7, (2991-3002), 10.1007/s12325-024-02810-3)', Advances in Therapy, 41, pp. 3014 - 3015, http://dx.doi.org/10.1007/s12325-024-02886-x
,2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880
,2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882
,2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038
,2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125
,2024, 'A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy', Indian Dermatology Online Journal, 15, pp. 854 - 855, http://dx.doi.org/10.4103/idoj.idoj_653_23
,2024, 'Atypical fixed drug eruption in confetti due to paracetamol', Dermatologica Sinica, 42, pp. 160 - 161, http://dx.doi.org/10.4103/ds.DS-D-23-00161
,2024, 'Environmental triggers of pemphigus vulgaris and bullous pemphigoid: a case control study', Frontiers in Medicine, 11, http://dx.doi.org/10.3389/fmed.2024.1441369
,2024, 'Predatory Conferences and Journals in Dermatology Are Black Widow Parties', Skinmed, 22, pp. 407 - 408
,2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215
,2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
,2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
,2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
,2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
,2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182
,2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
,2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
,2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
,2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
,2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
,2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144
,2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108
,2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033
,2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', JAAD International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016
,2023, 'ISID0459 - Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', , http://dx.doi.org/10.26226/m.641999e770c3630019098d8e
,